New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Allogene Therapeutics, Inc. (ALLO) vs Keros Therapeutics, Inc. (KROS)

Allogene Therapeutics, Inc. and Keros Therapeutics, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Keros Therapeutics, Inc. are of similar size ($231.1M and $223.5M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: −30.4% against −84.6%. Keros Therapeutics, Inc. has the higher net margin (−256.6% vs −335,973.6%) and the lower return on invested capital (−233.2% vs −119.4%). Across the 16 metrics below, Keros Therapeutics, Inc. leads on 11 and Allogene Therapeutics, Inc. on 5.

Valuation

Metric ALLO KROS Biotechnology median
P/E n/m n/m 8.49
P/S 45.61 4.00 8.56
P/B 0.55 0.79 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.43 0.55 0.69
EV/Sales (16.66) (0.71) 8.00
Earnings yield (101.61%) (25.36%) (35.81%)
Free cash flow yield (50.71%) (21.91%) (25.41%)

Profitability

Metric ALLO KROS Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (342,700.00%) (332.55%) 0.00%
Net margin (335,973.56%) (256.60%) 0.00%
Free cash flow margin (261,473.56%) (175.56%) 0.00%
Return on equity (49.29%) (12.56%) (51.58%)
Return on assets (36.69%) (11.76%) (45.91%)
Return on invested capital (119.37%) (233.22%) 0.00%

Growth

Metric ALLO KROS Biotechnology median
Revenue growth (TTM) (30.40%) (84.55%) 7.20%
EPS growth (last fiscal year) 34.09% 146.00% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALLO KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.79 18.14 4.79
Net debt to EBITDA 1.24 (4.16) 1.01

Dividend

Metric ALLO KROS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALLO KROS Biotechnology median
Market cap 231.06m 223.52m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack